Structuring a 35-Slide Presentation on Paraproteinemia: Clinical Spectrum, Diagnostic Work-Up, and Targeted Treatment
Your presentation should follow a systematic three-part structure: (1) Clinical Spectrum and Classification (slides 1-12), (2) Diagnostic Work-Up Algorithm (slides 13-22), and (3) Targeted Treatment Strategies (slides 23-35). This framework aligns with the most recent NCCN and EHA-EMN guidelines 1, 2 and provides a logical flow from recognition through management.
Section 1: Clinical Spectrum and Classification (Slides 1-12)
Opening Slides (1-3)
- Slide 1: Title and learning objectives
- Slide 2: Epidemiology - Multiple myeloma represents 1.8% of all cancers, 18% of hematologic malignancies, median age 69 years 1
- Slide 3: Spectrum overview diagram showing the continuum from MGUS → Smoldering MM → Symptomatic MM, plus related entities (Waldenström's, AL amyloidosis, POEMS, solitary plasmacytoma)
Disease Classification (4-8)
- Slide 4: MGUS criteria - monoclonal protein <3 g/dL, clonal plasma cells <10%, no end-organ damage 3
- Slide 5: Smoldering MM - monoclonal protein ≥3 g/dL and/or clonal plasma cells ≥10%, but no CRAB features (hypercalcemia, renal insufficiency, anemia, bone lesions) 3, 2
- Slide 6: Symptomatic MM diagnostic triad: ≥10% clonal plasma cells, presence of M-protein, evidence of end-organ damage (CRAB criteria with specific cutoffs: calcium ≥11.5 mg/dL, creatinine ≥2 mg/dL, hemoglobin <10 g/dL or 2 g/dL below normal, lytic lesions) 3
- Slide 7: Waldenström's macroglobulinemia - IgM paraproteinemia with lymphoplasmacytic infiltration, MYD88 L265P mutation in >90% 4, 5
- Slide 8: AL amyloidosis - clonal plasma cells producing light chains that deposit in organs (kidney, heart, liver, nerves), often with low plasma cell burden 6
Clinical Presentations (9-12)
- Slide 9: MM presentations - bone pain, pathologic fractures, anemia symptoms, recurrent infections, renal dysfunction, hypercalcemia symptoms
- Slide 10: Waldenström's - hyperviscosity syndrome (blurred vision, headache, bleeding), organomegaly, cytopenias, peripheral neuropathy, cryoglobulinemia 4
- Slide 11: AL amyloidosis red flags - nephrotic syndrome, restrictive cardiomyopathy, hepatomegaly, macroglossia, periorbital purpura, recurrent carpal tunnel syndrome, autonomic neuropathy 7, 8
- Slide 12: Paraproteinemic neuropathies - IgM anti-MAG (demyelinating pattern), POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes) 7, 8, 9
Section 2: Diagnostic Work-Up Algorithm (Slides 13-22)
Initial Laboratory Evaluation (13-16)
Slide 13: First-tier blood tests - CBC with differential, peripheral smear (look for Rouleaux formation), comprehensive metabolic panel including calcium, BUN/creatinine with calculated clearance, LDH, β2-microglobulin, albumin 1, 2
Slide 14: Paraprotein detection algorithm:
Slide 15: Serum free light chain (FLC) assay - essential for screening sensitivity, prognostication, monitoring oligosecretory disease and AL amyloidosis, required for stringent CR documentation 1. Caveat: Cannot replace 24-hour UPEP for monitoring measurable urinary M-protein; affected by renal function 3, 1
Slide 16: Specialized tests based on presentation:
Tissue Diagnosis (17-19)
Slide 17: Bone marrow evaluation - unilateral aspirate AND biopsy required, immunohistochemistry or flow cytometry to confirm clonality (kappa vs lambda restriction), CD138 staining for accurate plasma cell quantification 3, 1, 2
Slide 18: Cytogenetic studies - mandatory at diagnosis 1, 2:
- FISH panel: del(17p), del(13), t(4;14), t(11;14), t(14;16)
- Metaphase karyotyping provides additional information
- High-risk features: del(17p13), t(4;14), t(14;16), gain(1q), TP53 mutation 2
Slide 19: Amyloid confirmation when suspected - abdominal fat pad aspiration or organ biopsy with Congo red staining, immunohistochemistry to confirm AL type, genetic testing to exclude hereditary forms (especially in African-Americans and those with neuropathy) 6
Imaging Studies (20-22)
Slide 20: Skeletal survey - full radiographic series including spine, pelvis, skull, humeri, femurs for lytic lesions 6, 3, 1
Slide 21: Advanced imaging indications:
Slide 22: Waldenström's-specific imaging - CT chest/abdomen/pelvis to document organomegaly and lymphadenopathy at baseline 4
Section 3: Targeted Treatment Strategies (Slides 23-35)
Risk Stratification and Treatment Principles (23-25)
Slide 23: Updated high-risk MM criteria (IMS/IMWG 2025) 2 - presence of del(17p), t(4;14), t(14;16), gain(1q), TP53 mutation, elevated LDH, high plasma cell labeling index, extramedullary disease
Slide 24: Observation vs treatment decision tree:
- MGUS: Observe with serial monitoring 3
- Smoldering MM: Generally observe unless high-risk features; clinical trials encouraged 1, 2
- Symptomatic MM: Treat when CRAB criteria present 3, 1
- Waldenström's: Treat for symptomatic hyperviscosity, cytopenias, B symptoms, bulky organomegaly, neuropathy, or IgM >60 g/L (imminent hyperviscosity risk) 4
Slide 25: Transplant eligibility assessment - age, performance status, comorbidities, organ function; renal dysfunction is NOT a contraindication 6, 10
Multiple Myeloma Treatment (26-29)
Slide 26: Transplant-eligible patients - induction with triplet regimens (proteasome inhibitor + immunomodulatory drug + dexamethasone), followed by autologous stem cell transplant, then maintenance therapy 1, 2
Slide 27: Transplant-ineligible patients - continuous therapy with doublet or triplet regimens, dose adjustments for frailty 1, 2
Slide 28: Novel agents landscape - proteasome inhibitors (bortezomib, carfilzomib, ixazomib), immunomodulatory drugs (lenalidomide, pomalidomide), monoclonal antibodies (daratumumab, isatuximab), bispecific antibodies, CAR-T therapy for relapsed/refractory disease 2
Slide 29: Relapsed/refractory MM algorithm - consider prior therapies, duration of response, toxicity profile, patient preference, clinical trial availability 2
Waldenström's Macroglobulinemia Treatment (30-31)
Slide 30: First-line options 4, 11, 5:
- Rituximab-based combinations (with alkylating agents or proteasome inhibitors)
- Covalent BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib)
- BCL2 antagonist (venetoclax)
- Avoid rituximab monotherapy if IgM >5000 mg/dL (risk of IgM flare); use plasma exchange first 11
Slide 31: Emerging therapies - non-covalent BTK inhibitors, BTK degraders, antibody-drug conjugates, bispecific T-cell engagers in clinical trials 5
AL Amyloidosis and Supportive Care (32-34)
Slide 32: AL amyloidosis treatment 6:
- Goal: rapid reduction of light chain production
- Options: melphalan + dexamethasone, bortezomib-based regimens, lenalidomide + dexamethasone, daratumumab combinations
- Selected patients: high-dose melphalan with autologous stem cell transplant (higher treatment-related mortality but improved long-term outcomes)
- Organ-specific supportive care critical
Slide 33: Supportive care for MM 6, 10:
- Bone disease: bisphosphonates (zoledronic acid or pamidronate) monthly, reduce skeletal-related events and may improve survival
- Renal protection: hydration, avoid NSAIDs and IV contrast, plasmapheresis for acute renal failure (category 2B)
- Infection prevention: pneumococcal/influenza vaccines, IVIG for recurrent infections, PCP prophylaxis with high-dose dexamethasone, herpes prophylaxis with bortezomib
- Thromboprophylaxis: required with thalidomide or lenalidomide + dexamethasone combinations
- Anemia: erythropoietin, especially with renal failure
- Hypercalcemia: hydration, furosemide, bisphosphonates, steroids, calcitonin
- Hyperviscosity: plasmapheresis
Slide 34: Skeletal complications - radiation for symptomatic lesions (doses should not preclude future stem cell collection), orthopedic consultation for impending fractures or spinal cord compression, vertebroplasty/kyphoplasty for symptomatic compression fractures 6
Monitoring and Follow-Up (35)
- Slide 35: Response assessment and surveillance 6, 1:
- Quantitative immunoglobulins + M-protein quantification at least every 3 months
- CBC, differential, platelets, BUN, creatinine, calcium regularly
- Bone marrow biopsy as clinically indicated
- Skeletal survey annually or for new symptoms
- Free light chain assay for monitoring
- MRI for suspected progression
- Response criteria: Use IMWG Uniform Response Criteria for MM 3, 1, specific criteria for Waldenström's (CR requires absence of IgM by immunofixation, VGPR ≥90% reduction, PR ≥50% reduction) 4
Key Presentation Pitfalls to Avoid
Common diagnostic errors: Missing AL amyloidosis because SPEP was negative (always do immunofixation) 6; diagnosing paraproteinemic neuropathy as CIDP and treating with steroids/IVIG (ineffective and delays appropriate therapy) 7, 8, 9; using random urine samples instead of 24-hour collection 3; failing to perform FISH at diagnosis 1, 2.
Treatment mistakes: Starting therapy for asymptomatic smoldering MM or Waldenström's outside clinical trials 1, 4; using rituximab in Waldenström's with very high IgM without plasma exchange 11; withholding transplant due to renal dysfunction 6, 10; inadequate supportive care (no bisphosphonates, no thromboprophylaxis with IMiDs) 6, 10.
Monitoring failures: Using different assays for serial M-protein measurements (causes inaccurate trend assessment) 3, 1; relying solely on FLC for patients with measurable urinary M-protein 3, 1.
This structure provides comprehensive coverage while maintaining logical flow and emphasizing the most current evidence-based approaches to paraproteinemia management.